Rectal cancer - functional molecular prediction and targeting of radiotherapy response
- Prosjektnummer
- 2010014
- Ansvarlig person
- Anne Hansen Ree
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
PLoS One 2014;9(2):e89750. Epub 2014 feb 25
PMID: 24587009 - Inngår i doktorgradsavhandlingen
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.
J Enzyme Inhib Med Chem 2014 Oct 27. Epub 2014 okt 27
PMID: 25347767
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.
Int J Mol Sci 2014;15(12):22835-56. Epub 2014 des 9
PMID: 25501337
Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer.
Radiother Oncol 2013 May;107(2):178-83. Epub 2013 apr 17
PMID: 23602370
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer.
PLoS One 2013;8(5):e63723. Epub 2013 mai 10
PMID: 23675504
Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience.
Radiother Oncol 2013 Jul;108(1):3-16. Epub 2013 jul 3
PMID: 23830196
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Radiat Oncol 2012;7():165. Epub 2012 sep 27
PMID: 23017053 - Inngår i doktorgradsavhandlingen
Individualised treatment of metastatic cancer.
Tidsskr Nor Laegeforen 2012 Nov;132(21):2358-9.
PMID: 23160572
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.
PLoS One 2012;7(11):e50806. Epub 2012 nov 30
PMID: 23226389
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.
Radiat Oncol 2011;6():33. Epub 2011 apr 8
PMID: 21473790
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.
Angiogenesis 2011 Dec;14(4):481-9. Epub 2011 aug 11
PMID: 21833622 - Inngår i doktorgradsavhandlingen
Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases.
Acta Oncol 2010;49(1):42-9.
PMID: 20100143
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Lancet Oncol 2010 May;11(5):459-64. Epub 2010 apr 6
PMID: 20378407
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.
Int J Radiat Oncol Biol Phys 2010 Oct;78(2):555-62. Epub 2010 aug 2
PMID: 20675069
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.
J Clin Oncol 2010 Oct;28(29):e577-8; author reply e581-3. Epub 2010 aug 23
PMID: 20733124
Rectal Cancer – Functional Molecular Profiling and Targeting of Tumor Hypoxia in Radiation Response and Metastasis
- Disputert:
- juni 2014
- Hovedveileder:
- Anne Hansen Ree
- Kathrine Røe Redalen Prosjektdeltaker
- Øystein Fodstad Prosjektdeltaker
- Knut Håkon Hole Prosjektdeltaker
- Therese Seierstad Prosjektdeltaker
- Helga Hektoen Prosjektdeltaker
- Erta Kalanxhi Prosjektdeltaker
- Svein Dueland Prosjektdeltaker
- Kjersti Flatmark Biveileder
- Anne Hansen Ree Prosjektleder
- Marie Grøn Sælen Doktorgradsstipendiat
- Torveig Weum Abrahamsen Prosjektdeltaker
- Kathrine Røe Prosjektdeltaker
- Helga Helseth Hektoen Prosjektdeltaker
- Torbjørn Furre Prosjektdeltaker
- Alexandr Kristian Prosjektdeltaker
- Sigurd Folkvord Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport